管滢芸,李晓烨,张弛,张宁,王之颖,任金妹,卞晓岚

• 1:上海交通大学医学院附属瑞金医院药剂科
• 2:复旦大学附属中山医院药剂科
• 3:上海交通大学医学院附属仁济医院药剂科
• 4:上海市徐汇区中心医院药剂科

摘要(Abstract)：

目的 以药品临床价值为导向，对沙库巴曲缬沙坦治疗原发性高血压的临床综合价值进行评价，为临床合理用药和相关用药决策提供参考。方法 采用文献研究的方法，基于当前可获得的证据，围绕沙库巴曲缬沙坦治疗原发性高血压的安全性、有效性、经济性、创新性、适宜性和可及性6个维度，开展临床综合评价。结果 安全性方面，沙库巴曲缬沙坦与血管紧张素受体拮抗剂类（ARB）等降压药物具有相似的安全性；有效性方面，沙库巴曲缬沙坦较ARB类等降压药物具有更强的降压效果，且对患者心功能也有显著改善；经济性方面，沙库巴曲缬沙坦治疗原发性高血压的成本效果优于阿利沙坦酯和缬沙坦；创新性方面，沙库巴曲缬沙坦是心血管领域首个双活性物质的共晶体结构药物，作为全球首个上市的血管紧张素受体-脑啡肽酶抑制剂（ARNI）类药物，通过同时作用于利尿钠肽系统（NPS）和肾素-血管紧张素-醛固酮系统（RAAS），发挥多途径降压和靶器官保护作用；适宜性方面，沙库巴曲缬沙坦具有良好的技术特点适宜性，使用方便且便于存储；可及性方面，沙库巴曲缬沙坦的价格水平较低，具有较好的可获得性和可负担性。结论 沙库巴曲缬沙坦作为全球首个上市的ARNI类药物，在治疗原发性高血压方面具有良好的安全性、有效性、经济性、创新性、适宜性和可及性，通过临床的合理使用，有望引领高血压治疗管理模式由单纯降压步入全程心血管事件风险管控。

关键词(KeyWords)： 沙库巴曲缬沙坦;原发性高血压;药品临床综合评价;血管紧张素受体-脑啡肽酶抑制剂

Abstract:

Keywords:

基金项目(Foundation): 上海市药学会—药品临床综合评价与药物治疗路径研究项目（编号SHYXH-ZP-2021-002）

作者(Author): 管滢芸,李晓烨,张弛,张宁,王之颖,任金妹,卞晓岚

DOI: 10.19577/j.1007-4406.2023.05.005

参考文献(References)：

• [1] WILLIAMS B, MANCIA G, SPIERING W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension[J]. Eur Heart J, 2018, 39(33):3021.
• [2] MILLS K T, BUNDY J D, KELLY T N, et al. Global disparities of hypertension prevalence and control:a systematic analysis of population-based studies from 90 countries[J]. Circulation,2016, 134(6):441.
• [3] WANG Z W, CHEN Z, ZHANG L F, et al. Status of hypertension in China:results from the China hypertension survey, 2012-2015[J].Circulation, 2018, 137(22):2344.
• [4] LEWINGTON S, CLARKE R, QIZILBASH N, et al. Age-specific relevance of usual blood pressure to vascular mortality:a metaanalysis of individual data for one million adults in 61 prospective studies[J]. Lancet, 2002, 360(9349):1903.
• [5] BUNDY J D, HE J. Hypertension and related cardiovascular disease burden in China[J]. Ann Glob Health, 2016, 82(2):227.
• [6] ZOIS N E, BARTELS E D, HUNTER I, et al. Natriuretic peptides in cardiometabolic regulation and disease[J]. Nat Rev Cardiol,2014, 11(7):403.
• [7]中国高血压联盟《动态血压监测指南》委员会. 2020中国动态血压监测指南[J].中国循环杂志, 2021, 36(4):313.
• [8]中国医疗保健国际交流促进会高血压分会,中国医师协会心血管分会,中国高血压联盟,等.沙库巴曲缬沙坦在高血压患者临床应用的中国专家建议[J].中华高血压杂志, 2021, 29(2):108.
• [9]中华人民共和国国家卫生健康委员会.国家卫生健康委办公厅关于规范开展药品临床综合评价工作的通知[EB/OL].(2021-07-28).http://wsjkw.hebei.gov.cn/zcfg2/380991. jhtml.
• [10]国家药物和卫生技术综合评估中心.国家药物和卫生技术综合评估中心关于发布心血管病、抗肿瘤、儿童药品临床综合评价技术指南的通知[EB/OL].(2022-06-29). http://www.nhei.cn/nhei/znfb/202206/c01d87a290664b01bf42a9dad769d69f.shtml.
• [11] BENKHALTI M, ESPINOZA M, COOKSON R, et al. Development of a checklist to guide equity considerations in health technology assessment[J]. Int J Technol Assess Health Care, 2021, 37:e17.
• [12] SHEA B J, GRIMSHAW J M, WELLS G A, et al. Development of AMSTAR:a measurement tool to assess the methodological quality of systematic reviews[J]. BMC Med Res Methodol, 2007, 7:10.
• [13] HUSEREAU D, DRUMMOND M, PETROU S, et al. Consolidated health economic evaluation reporting standards(CHEERS)statement[J]. BJOG, 2013, 120(6):765.
• [14] MALIK A H, ARONOW W S. Efficacy of sacubitril/valsartan in hypertension[J]. Am J Ther, 2022, 29(3):e322.
• [15] WU H X, LIU K K, LI B N, et al. Efficacy and safety of sacubitril/valsartan in the treatment of middle-aged and elderly patients with hypertension:a systematic review and meta-analysis of randomized controlled trials[J]. Ann Palliat Med, 2022, 11(5):1811.
• [16] ZHANG Y L, ZHAO X Y, HUANG H, et al. Network meta-analysis of sacubitril/valsartan for the treatment of essential hypertension[J]. Clin Res Cardiol, 2023, 112(7):855.
• [17] CHUA S K, LAI W T, CHEN L C, et al. The antihypertensive effects and safety of LCZ696 in patients with hypertension:a systemic review and meta-analysis of randomized controlled trials[J]. J Clin Med, 2021, 10(13):2824.
• [18] YANG S, ZHANG H Z, YANG P P, et al. Efficacy and safety of LCZ696 for short-term management of essential hypertension compared with ARBs:a meta-analysis of randomized controlled trials[J]. J Cardiovasc Pharmacol, 2021, 77(5):650.
• [19] ZHENG L, XIA B B, ZHANG X Q, et al. A meta-analysis on the effect and safety of LCZ696 in the treatment of hypertension[J].Cardiol Res Pract, 2021, 2021:8867578.
• [20] VECCHIS R D, SORECA S, ARIANO C. Anti-hypertensive effect of sacubitril/valsartan:a meta-analysis of randomized controlled trials[J]. Cardiol Res, 2019, 10(1):24.
• [21] LI Q Q, LI L N, WANG F H, et al. Effect and safety of LCZ696 in the treatment of hypertension:a meta-analysis of 9 RCT studies[J].Medicine, 2019, 98(28):e16093.
• [22] GENG Q, YAN R Q, WANG Z Z, et al. Effects of LCZ696(s a c u b i t r i l/v a l s a r t a n)o n b l o o d p r e s s u r e i n p a t i e n t s w i t h hypertension:a meta-analysis of randomized controlled trials[J].Cardiology, 2020, 145(9):589.
• [23] LI B, ZHAO Y H, YIN B, et al. Safety of the neprilysin/reninangiotensin system inhibitor LCZ696[J]. Oncotarget, 2017,8(47):83323.
• [24]陈灿,李晓烨,田丹,等.沙库巴曲缬沙坦治疗高血压有效性及安全性的系统评价[J].中国医院用药评价与分析, 2022, 22(9):1127.
• [25]郑丽,张续乾,孙雪林,等.沙库巴曲缬沙坦钠治疗高血压有效性和安全性的Meta分析[J].中国药物警戒, 2022, 19(10):1118.
• [26]时庆平,陈飞鸿,兰玲,等.沙库巴曲/缬沙坦治疗原发性高血压效果和安全性的Meta分析[J].广西医学, 2021, 43(9):1124.
• [27]邓小伟.沙库巴曲缬沙坦治疗轻中度高血压的疗效及安全性的meta分析[D].重庆:重庆医科大学, 2020.
• [28]闫静静.沙库巴曲缬沙坦钠治疗原发性高血压安全性的Meta分析[D].郑州:郑州大学, 2018.
• [29]李婉婧.沙库巴曲缬沙坦在难治性高血压患者中的疗效及meta分析[D].大连:大连医科大学, 2022.
• [30] DONG X Y, HE X N, WU J. Cost effectiveness of the first-inclass ARNI(sacubitril/valsartan)for the treatment of essential hypertension in a Chinese setting[J]. PharmacoEconomics,2022, 40(12):1187.
• [31] LOU Y K, YU Y, LIU J X, et al. Sacubitril-valsartan for the treatment of hypertension in China:a cost-utility analysis based on meta-analysis of randomized controlled trials[J]. Front Public Health, 2022, 10:959139.
• [32] GU J, NOE A, CHANDRA P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor(ARNi)[J]. J Clin Pharmacol, 2010,50(4):401.
• [33]国家统计局. 2021年居民收入和消费支出情况[EB/OL](2022-01-17). http://www.gov.cn/shuju/2022-01/17/content_5668748.htm.
• [34]国家统计局.第七次全国人口普查数据[EB/OL].(2021-05-11).http://www.stats.gov.cn/ztjc/zdtjgz/zgrkpc/dqcrkpc/ggl/202105/t20210519_1817693.html.